Dihydrolipoamide dehydrogenase (DLD) is a mitochondrial enzyme that plays a vital role in energy metabolism in eukaryotes. This enzyme is required for the complete reaction of at least five different multi-enzyme complexes. Additionally, DLD is a flavoenzyme oxidoreductase that contains a reactive disulfide bridge and a FAD cofactor that are directly involved in catalysis. The enzyme associates into tightly bound homodimers required for its enzymatic activity.
The protein encoded by the DLD gene comes together with another protein to form a dimer in the central metabolic pathway. Several amino acids within the catalytic pocket have been identified as important to DLD function, including R281 and N473. Although the overall fold of the human enzyme is similar to that of yeast, the human structure is different in that it has two loops that extend from the general protein structure and into the FAD binding sites. When bound the NAD+ molecule, required for catalysis, is not close to the FAD moiety. However, when NADH is bound instead, it is stacked directly op top of the FAD central structure. The current hE3 structures show directly that the disease-causing mutations occur at three locations in the human enzyme: the dimer interface, the active site, and the FAD and NAD(+)-binding sites.
The DLD homodimer functions as the E3 component of the pyruvate, α-ketoglutarate, and branched-chain amino acid-dehydrogenase complexes and the glycine cleavage system, all in the mitochondrial matrix. In these complexes, DLD converts dihydrolipoic acid and NAD+ into lipoic acid and NADH. DLD also has diaphorase activity, being able to catalyze the oxidation of NADH to NAD+ by using different electron acceptors such as O2, labile ferric iron, nitric oxide, and ubiquinone. DLD is thought to have a pro-oxidant role by reducing oxygen to a superoxide or ferric to ferrous iron, which then catalyzes production of hydroxyl radicals. Diaphorase activity of DLD may have an antioxidant role through its ability to scavenge nitric oxide and to reduce ubiquinone to ubiquinol. The dihyrolipamide dehydrogenase gene is known to have multiple splice variants.
Certain DLD mutations can simultaneously induce the loss of a primary metabolic activity and the gain of a moonlighting proteolytic activity. The moonlighting proteolytic activity of DLD is revealed by conditions that destabilize the DLD homodimer and decrease its DLD activity. Acidification of the mitochondrial matrix, as a result of ischemia-reperfusion injury, can disrupt the quaternary structure of DLD leading to decreased dehydrogenase activity and increased diaphorase activity. The moonlighting proteolytic activity of DLD could also arise under pathological conditions. Proteolytic activity can further complicate the reduction in energy metabolism and an increase in oxidative damage as a result of decreased DLD activity and an increase in diaphorase activity respectively. With its proteolytic function, DLD removes a functionally vital domain from the N-terminus of frataxin, a mitochondrial protein involved in iron metabolism and antioxidant protection.
In humans, mutations in DLD are linked to a severe disorder of infancy with failure to thrive, hypotonia, and metabolic acidosis. DLD deficiency manifests itself in a great degree of variability, which has been attributed to varying effects of different DLD mutations on the stability of the protein and its ability to dimerize or interact with other components of the three α-ketoacid dehydrogenase complexes. With its proteolytic function, DLD causes a deficiency in frataxin, which leads to the neurodegenerative and cardiac disease, Friedreich ataxia. Future research hopes to assess how the proteolytic activity of DLD contributes to the symptoms of DLD deficiency, Friedreich ataxia, and ischemia reperfusion injury and whether this activity could be a target for therapy for these conditions.
^Otulakowski G, Robinson BH (December 1987). "Isolation and sequence determination of cDNA clones for porcine and human lipoamide dehydrogenase. Homology to other disulfide oxidoreductases". J. Biol. Chem.262 (36): 17313–8. PMID3693355.
^Ciszak EM, Makal A, Hong YS, Vettaikkorumakankauv AK, Korotchkina LG, Patel MS (2006). "How dihydrolipoamide dehydrogenase-binding protein binds dihydrolipoamide dehydrogenase in the human pyruvate dehydrogenase complex". The Journal of Biological Chemistry281 (1): 648–55. doi:10.1074/jbc.M507850200. PMID16263718.
^Kim, H (31 March 2005). "Asparagine-473 residue is important to the efficient function of human dihydrolipoamide dehydrogenase.". Journal of biochemistry and molecular biology38 (2): 248–52. PMID15826505.
^Wang, YC; Wang, ST; Li, C; Chen, LY; Liu, WH; Chen, PR; Chou, MC; Liu, TC (January 2008). "The role of amino acids T148 and R281 in human dihydrolipoamide dehydrogenase.". Journal of biomedical science15 (1): 37–46. PMID17960497.
^Brautigam, CA; Chuang, JL; Tomchick, DR; Machius, M; Chuang, DT (15 July 2005). "Crystal structure of human dihydrolipoamide dehydrogenase: NAD+/NADH binding and the structural basis of disease-causing mutations.". Journal of molecular biology350 (3): 543–52. PMID15946682.
^Carothers DJ, Pons G, Patel MS (1989). "Dihydrolipoamide dehydrogenase: functional similarities and divergent evolution of the pyridine nucleotide-disulfide oxidoreductases". Archives of Biochemistry and Biophysics268 (2): 409–25. doi:10.1016/0003-9861(89)90309-3. PMID2643922.
^Petrat F, Paluch S, Dogruöz E, Dörfler P, Kirsch M, Korth HG, Sustmann R, de Groot H (2003). "Reduction of Fe(III) ions complexed to physiological ligands by lipoyl dehydrogenase and other flavoenzymes in vitro: implications for an enzymatic reduction of Fe(III) ions of the labile iron pool". The Journal of Biological Chemistry278 (47): 46403–13. doi:10.1074/jbc.M305291200. PMID12963736.
^Yoneyama, K; Shibata, R; Igarashi, A; Kojima, S; Kodani, Y; Nagata, K; Kurose, K; Kawase, R; Takeshita, T; Hattori, S (2014). "Proteomic identification of dihydrolipoamide dehydrogenase as a target of autoantibodies in patients with endometrial cancer". Anticancer research34 (9): 5021–7. PMID25202086.edit
^Igamberdiev AU, Bykova NV, Ens W, Hill RD (2004). "Dihydrolipoamide dehydrogenase from porcine heart catalyzes NADH-dependent scavenging of nitric oxide". FEBS Letters568 (1-3): 146–50. doi:10.1016/j.febslet.2004.05.024. PMID15196936.
^Olsson JM, Xia L, Eriksson LC, Björnstedt M (1999). "Ubiquinone is reduced by lipoamide dehydrogenase and this reaction is potently stimulated by zinc". FEBS Letters448 (1): 190–2. doi:10.1016/s0014-5793(99)00363-4. PMID10217438.
^ abXia L, Björnstedt M, Nordman T, Eriksson LC, Olsson JM (2001). "Reduction of ubiquinone by lipoamide dehydrogenase. An antioxidant regenerating pathway". European Journal of Biochemistry / FEBS268 (5): 1486–90. doi:10.1046/j.1432-1327.2001.02013.x. PMID11231302.
^Klyachko NL, Shchedrina VA, Efimov AV, Kazakov SV, Gazaryan IG, Kristal BS, Brown AM (2005). "pH-dependent substrate preference of pig heart lipoamide dehydrogenase varies with oligomeric state: response to mitochondrial matrix acidification". The Journal of Biological Chemistry280 (16): 16106–14. doi:10.1074/jbc.M414285200. PMID15710613.
^O'Neill HA, Gakh O, Park S, Cui J, Mooney SM, Sampson M, Ferreira GC, Isaya G (2005). "Assembly of human frataxin is a mechanism for detoxifying redox-active iron". Biochemistry44 (2): 537–45. doi:10.1021/bi048459j. PMID15641778.
^Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Cañizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel JL, Cocozza S, Koenig M, Pandolfo M (1996). "Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion". Science271 (5254): 1423–7. doi:10.1126/science.271.5254.1423. PMID8596916.
Brautigam CA, Chuang JL, Tomchick DR et al. (2005). "Crystal structure of human dihydrolipoamide dehydrogenase: NAD+/NADH binding and the structural basis of disease-causing mutations.". J. Mol. Biol.350 (3): 543–52. doi:10.1016/j.jmb.2005.05.014. PMID15946682.
Reed LJ, Hackert ML (1990). "Structure-function relationships in dihydrolipoamide acyltransferases.". J. Biol. Chem.265 (16): 8971–4. PMID2188967.
Ciszak EM, Makal A, Hong YS et al. (2006). "How dihydrolipoamide dehydrogenase-binding protein binds dihydrolipoamide dehydrogenase in the human pyruvate dehydrogenase complex.". J. Biol. Chem.281 (1): 648–55. doi:10.1074/jbc.M507850200. PMID16263718.
Asano K, Matsushita T, Umeno J et al. (2009). "A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population.". Nat. Genet.41 (12): 1325–9. doi:10.1038/ng.482. PMID19915573.
OdiÃ¨vre MH, Chretien D, Munnich A et al. (2005). "A novel mutation in the dihydrolipoamide dehydrogenase E3 subunit gene (DLD) resulting in an atypical form of alpha-ketoglutarate dehydrogenase deficiency.". Hum. Mutat.25 (3): 323–4. doi:10.1002/humu.9319. PMID15712224.
Sugden MC, Holness MJ (2003). "Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs.". Am. J. Physiol. Endocrinol. Metab.284 (5): E855–62. doi:10.1152/ajpendo.00526.2002. PMID12676647.
Brown AM, Gordon D, Lee H et al. (2004). "Association of the dihydrolipoamide dehydrogenase gene with Alzheimer's disease in an Ashkenazi Jewish population.". Am. J. Med. Genet. B Neuropsychiatr. Genet.131B (1): 60–6. doi:10.1002/ajmg.b.30008. PMID15389771.
Wang YC, Wang ST, Li C et al. (2007). "The role of N286 and D320 in the reaction mechanism of human dihydrolipoamide dehydrogenase (E3) center domain.". J. Biomed. Sci.14 (2): 203–10. doi:10.1007/s11373-006-9136-0. PMID17171578.
Foster LJ, Rudich A, Talior I et al. (2006). "Insulin-dependent interactions of proteins with GLUT4 revealed through stable isotope labeling by amino acids in cell culture (SILAC).". J. Proteome Res.5 (1): 64–75. doi:10.1021/pr0502626. PMID16396496.
Hiromasa Y, Fujisawa T, Aso Y, Roche TE (2004). "Organization of the cores of the mammalian pyruvate dehydrogenase complex formed by E2 and E2 plus the E3-binding protein and their capacities to bind the E1 and E3 components.". J. Biol. Chem.279 (8): 6921–33. doi:10.1074/jbc.M308172200. PMID14638692.
Wynn RM, Kato M, Machius M et al. (2004). "Molecular mechanism for regulation of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase complex by phosphorylation.". Structure12 (12): 2185–96. doi:10.1016/j.str.2004.09.013. PMID15576032.